The Filing Desk

BioCryst Pharmaceuticals vs Repligen

BioCryst Pharmaceuticals BCRX · Repligen RGEN · Biotechnology

BioCryst Pharmaceuticals reported revenue of $875 million in fiscal 2025, 1.2 times Repligen's $738 million in fiscal 2025. BioCryst Pharmaceuticals' revenue grew 94.1% in its latest year, and Repligen's grew 16.4%. BioCryst Pharmaceuticals had an operating margin of 39.0%, against 7.5% at Repligen. Free cash flow was $345 million at BioCryst Pharmaceuticals and $94 million at Repligen.

Side by side

BioCryst PharmaceuticalsRepligen
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$875M$738M
Revenue growth94.1%16.4%
Revenue growth a year, last 5 years117.9%15.0%
Gross margin97.8%52.3%
Operating margin39.0%7.5%
Net margin30.2%6.6%
Free cash flow$345M$94M
Free cash flow margin39.4%12.7%
Return on capital—2.4%
Net debt to EBITDA−0.8x−1.7x
Dividends and buybacks$0M$0M
Change in diluted share count5.8%—
Last close$7.61$167.79
P/E at the last close——
Insider trades, last 12 monthssold $4.1 millionsold $7.2 million
Piotroski F-score7 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BioCryst PharmaceuticalsRepligen
Operating margin
Percent of revenue
BioCryst PharmaceuticalsRepligen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioCryst PharmaceuticalsRepligen

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioCryst Pharmaceuticals and Repligen pages.